Fortress Biotech (FBIO) AI Stock Analysis

• Market Cap: $73.49M
• Dividend Yield: N/A
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: -0.32%
• EPS Growth: 94.05%
• Country: US
• Employees: 101
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 29,754,753
• 10 Day Avg. Volume: 683,913
• 30 Day Avg. Volume: 1,343,678
• PEG Ratio: 0.01
• Price to Book (P/B): 1.86
• Price to Sales (P/S): 0.73
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 0.70
• Enterprise Value/Gross Profit: 1.07
• Enterprise Value/Ebitda: -1.13
• 1Y Price Target: $10.75
• Price Target Upside: 321.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $2.50 ▼(-1.96% Downside)

The overall stock score is primarily impacted by the company's financial instability, characterized by declining revenues and high leverage. While the earnings call provided some positive insights regarding new product performance and future growth potential, the technical analysis and valuation metrics remain weak, contributing to a lower overall score.

Positive Factors

Strategic Milestones

Strategic milestones, including subsidiary acquisitions and sales, validate Fortress Biotech's business model and enhance future revenue potential through contingent payments and royalties.

Product Launch Success

The successful launch of EMROSI and its strong market adoption indicate robust product development capabilities and potential for sustained revenue growth.

Pipeline Progress

Advancements in the late-stage pipeline, including Phase 3 trials for dotinurad, suggest potential future product approvals and revenue streams, enhancing long-term growth prospects.

Negative Factors

Financial Instability

Ongoing financial instability, characterized by declining revenues and high leverage, poses risks to operational sustainability and limits strategic flexibility.

Negative Cash Flow

Negative cash flows highlight challenges in covering operational expenses, necessitating external financing and potentially impacting long-term financial health.

Decline in Legacy Products

Declining revenues from legacy products due to generic competition reduce overall revenue base and may hinder short-term financial performance.

Fortress Biotech Business Overview & Revenue Model

Company Description

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative drug candidates in the fields of oncology, immunology, and other therapeutic areas. The company operates through a diverse portfolio of subsidiaries and collaborations, aiming to bring novel therapies to market that address unmet medical needs. Fortress Biotech's core products include several proprietary drug candidates and partnerships with various biopharmaceutical companies to enhance its research and development efforts.

How the Company Makes Money

Fortress Biotech generates revenue primarily through the development and commercialization of its drug candidates. Key revenue streams include milestone payments from partnerships with larger pharmaceutical companies, royalty revenue from product sales, and revenues derived from licensing agreements. The company often enters into collaborations with established firms to leverage their development expertise and market reach, which can lead to significant upfront payments, as well as potential future royalties based on the success of the partnered products. Additionally, Fortress Biotech may receive funding through public or private offerings to support its research and development initiatives.

Fortress Biotech Financial Statement Overview

Summary

Fortress Biotech is facing financial instability with declining revenues, persistent losses, and high leverage. The company shows negative profitability metrics and potential liquidity risks due to high debt levels. Cash flows are insufficient to cover operational needs, raising concerns about sustainability without external financing.

Income Statement

Fortress Biotech has experienced a challenging financial period with declining revenues from 2023 to 2024, and persistent net losses. The gross profit margin remains positive at approximately 100% due to negligible cost of goods sold, but the company faces a negative EBIT and EBITDA margin, indicating operational inefficiencies. The net profit margin is significantly negative, reflecting high net losses relative to total revenue. Revenue growth was negative in the latest year, indicating a contraction in sales.

Balance Sheet

The balance sheet shows high leverage with a debt-to-equity ratio indicating significant reliance on debt financing. Stockholders' equity has decreased over time, impacting the equity ratio negatively. The return on equity is negative due to continuous net losses, suggesting poor return on shareholders' investments. The current debt levels could pose a risk if profitability does not improve.

Cash Flow

The cash flow analysis reveals negative operating cash flows, indicating that the company is not generating sufficient cash from operations to cover its expenses. Free cash flow is also negative, pointing to challenges in creating value for shareholders. The operating cash flow to net income ratio is unfavorable due to significant cash outflows and net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.30M	57.67M	84.51M	75.74M	68.79M	45.60M
Gross Profit	41.01M	36.80M	61.62M	44.97M	36.71M	31.00M
EBITDA	-38.77M	-104.49M	-135.72M	-193.69M	-146.17M	-87.82M
Net Income	3.99M	-46.00M	-60.64M	-86.58M	-64.70M	-46.53M
Balance Sheet
Total Assets	181.41M	144.22M	167.53M	294.30M	396.50M	333.41M
Cash, Cash Equivalents and Short-Term Investments	86.22M	57.26M	80.93M	178.27M	305.74M	233.35M
Total Debt	68.29M	75.96M	88.59M	127.34M	74.98M	89.08M
Total Liabilities	116.22M	145.87M	165.94M	244.28M	170.63M	136.41M
Stockholders Equity	55.86M	22.74M	22.54M	41.72M	108.67M	100.34M
Cash Flow
Free Cash Flow	-66.14M	-95.19M	-136.32M	-182.46M	-132.89M	-90.85M
Operating Cash Flow	-66.14M	-80.19M	-128.22M	-179.40M	-116.54M	-83.68M
Investing Cash Flow	-4.88M	-15.00M	-2.10M	-22.93M	40.51M	-7.16M
Financing Cash Flow	97.54M	70.64M	32.74M	75.32M	148.99M	172.41M

Fortress Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBIO, the sentiment is Negative. The current price of 2.55 is below the 20-day moving average (MA) of 2.56, below the 50-day MA of 2.88, and above the 200-day MA of 2.15, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 43.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBIO.

Fortress Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	53 Neutral	$76.47M	-0.69	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FBIO	47 Neutral	$73.49M	-2.16	10.35%	―	-0.32%	94.05%
EQ	41 Neutral	$85.68M	-2.54	-90.24%	―	-90.43%	-382.07%
UNCY	28 Underperform	$118.63M	―	-102.47%	―	―	66.05%
CVM	27 Underperform	$56.43M	-0.72	-328.04%	―	―	42.29%

Fortress Biotech Corporate Events

Journey Medical Corporation Reports Strong Q3 2025 Growth

Journey Medical Corporation is a commercial-stage pharmaceutical company that specializes in selling and marketing FDA-approved prescription products for dermatological conditions. Based in Scottsdale, Arizona, the company is known for its efficient sales and marketing model and its portfolio of eight branded prescription drugs.

Fortress Biotech’s Earnings Call Highlights EMROSI Success

Fortress Biotech Inc’s recent earnings call painted a picture of robust growth and optimism, despite some hurdles. The company celebrated significant revenue growth, driven by the successful launch of EMROSI, which has shown promising results in the market. However, challenges such as declining legacy product revenues and delays in health plan formulary adoption for EMROSI were also acknowledged. Overall, the sentiment was positive, with a strong belief in EMROSI’s potential and future revenue growth.

Fortress Biotech Receives FDA Response on CUTX-101

On October 1, 2025, Fortress Biotech, Inc. announced that the U.S. Food and Drug Administration issued a complete response letter for their product CUTX-101 (copper histidinate). This development may impact the company’s operations and its positioning within the pharmaceutical industry, as regulatory feedback can influence product timelines and stakeholder expectations.

The most recent analyst rating on (FBIO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.

Journey Medical’s Q2 2025: Emrosi Gains Traction

Journey Medical Corporation, a commercial-stage pharmaceutical company based in Scottsdale, Arizona, focuses on selling and marketing FDA-approved prescription products for dermatological conditions. The company is known for its efficient sales and marketing model and currently markets eight branded prescription drugs.